Acute bacterial meningitis in infants and children: Epidemiology and management

Pediatric Drugs

Volumn 13, Issue 6, 2011, Pages 385-400

  Agrawal, Shruti ^a   Nadel, Simon ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CORTICOSTEROID; DAPTOMYCIN; DEXAMETHASONE; GATIFLOXACIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; LINEZOLID; MENINGOCOCCUS VACCINE; MEROPENEM; MOXIFLOXACIN; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; INFLAMMATION; MENINGOCOCCOSIS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA MENINGITIDIS; NEWBORN INFECTION; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; BLOOD-BRAIN BARRIER; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; MENINGITIS, BACTERIAL;

EID: 80054765318     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11593340-000000000-00000     Document Type: Review

References (189)

1. Makwana N, Riordan FAI. Bacterial meningitis: the impact of vaccination. CNS Drugs 2007; 21: 355-66 (Pubitemid 46698501)
2. World Health Organization. New and under-utilized vaccines implementation (NUVI): bacterial meningitis [online]. Available from URL: http://www.who.int/ nuvi/meningitis/en/index.html [Accessed 2011 Apr 13]
3. World Health Organization. Meningococcal meningitis [online]. Available from URL : http://www.who.int/mediacentre/factsheets/fs141/en/index.html [Accessed 2011 Feb 18]
4. Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 317-28
5. Pfister HW, Feiden W, Einhaupl KM. Spectrum of complications during bacterial meningitis in adults: results of a prospective clinical study. Arch Neurol 1993; 50: 575-81 (Pubitemid 23165584)
6. Segretti J, Harris AA. Acute bacterial meningitis. Infect Dis Clin North Am 1996; 10: 707-809
7. Wenger JD, Hightower AW, Facklam RR, et al. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis 1990; 162: 1316-23
8. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 24: B51-63
9. Martin M, Casellas JM, Madhi SA, et al. Impact of Haemophilus influenzae type b conjugate vaccine in South Africa and Argentina. Pediatr Infect Dis J 2004; 23: 842-7 (Pubitemid 40221028)
10. Adegbola RA, Secka O, LahaiG, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after introduction of routine immunisation with aHib conjugate vaccine: a prospective study. Lancet 2005; 366: 144-50 (Pubitemid 40991215)
11. Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 1998; 17 (9 Suppl.): S132-6 (Pubitemid 28460556)
12. Dagan R, Fraser D, Roitman M, et al. Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group. Vaccine 1999; 17: 134-41 (Pubitemid 28494112)
13. Murphy TV, Pastor P, Medley F, et al. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1993; 122: 517-23 (Pubitemid 23093573)
14. Adegbola RA, Mulholland EK, Secka O, et al. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 1998; 177: 1758-61 (Pubitemid 28243612)
15. World Health Organization. Progress introducing Haemophilus influenzae type b vaccine in low-income countries, 2004-2008. Wkly Epidemiol Rec 2008; 83: 61-8
16. Rossi IA, Zuber PL, Dumolard L, et al. Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends. Vaccine 2007; 25: 7075-80 (Pubitemid 47464682)
17. Watt JP, Wolfson LJ, OBrien KL. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374: 903-11
18. Obonyo CO, Lau J. Efficacy of haemophilus influenzae type b vaccination of children: a meta-analysis. Eur J Microbiol Infect Dis 2006 Feb; 25 (2): 90-7 (Pubitemid 43333669)
19. Ladhani S, Slack MP, Heath PT, et al. Invasive Haemophilus influenzae disease, Europe, 1996-2006. Emerg Infect Dis 2010; 16: 455-63
20. Centers for Disease Control and Prevention. Global routine vaccination coverage, 2009.MMWRMorbMortalWkly Rep 2010 Oct 29 59 42 1367-71
21. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization: WHO position paper. Wkly Epidemiol Rec 2007; 82: 93-104
22. Lynch JP, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010; 16: 217-25
23. World Health Organization. Pneumococcal vaccines. Wkly Epidemiol Rec 2003; 78: 110-9
24. OBrien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902
25. Lexau C, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294: 2043-51 (Pubitemid 41539937)
26. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009; (4): CD004977
27. Whitney C, Farley M, Hadler J, et al. Decline in invasive pneumococcal disease after introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46 (Pubitemid 36514704)
28. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41
29. Pavia M, Bianco A, Nobile CG, et al. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009; 123: e1103-10
30. Lacapa R, Bliss SJ, Larzelere-Hinton F, et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 2008; 47: 476-84
31. Park IH, Pritchard DG, Carlee R, et al. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007; 45: 1225-33 (Pubitemid 46626489)
32. Lynch III JP, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009; 30: 210-38
33. Rodgers GL, Arguedas A, Cohen R, et al. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications of pneumococcal conjugate vaccines. Vaccine 2009; 27: 3802-10
34. Hsieh YC, Lin PY, Chiu CH, et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009; 27: 3313-8
35. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49: e23-9
36. Moore MR. Rethinking replacement and resistance. J Infect Dis 2009; 199: 771-3
37. Levy C, Varon E, Bingen E, et al. Pneumococcal meningitis in French children before and after the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2011; 30: 168-70
38. Carvalho MDG, Pimenta FC, Gertz Jr RE, et al. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol 2009; 47: 554-9
39. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized double-blinded, placebo-controlled trial. Lancet 2005; 365: 1139-46 (Pubitemid 40417563)
40. Timo V, Jacek W, Bertrand C. Immunogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28: S66-76
41. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children. Advisory Committee on Immunization Practices (ACIP).MMWR 2010 59:9 258-61
42. Department of Health, Social Services and Public Safety. Change to the childhood immunisation schedule: vaccinations at 12 and 13 months of age (MMR, PCV13 and Hib/Men C) [online]. Available from URL http://www.dhsspsni.gov.uk/ hss-md-4-2011.pdf [Accessed 2011 Apr 11]
43. Grijalva CG, Pelton SI. A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Curr Opin Pediatr 2011; 23: 98-104
44. Ogilive I, Khoury AE, Cui Y, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 2009; 27: 4891-904
45. Lynch III JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009; 30: 189-209
46. Vila-Corcoles A, Ochoa-Gondar O, Guzman JA, et al. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years of older. BMC Infect Dis 2010; 10: 73
47. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007; 26: 123-8 (Pubitemid 46183361)
48. Dagan R, Klugman KP. Impact of pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008; 8: 785-95
49. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369: 2196-210 (Pubitemid 46977462)
50. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344: 1378-88
51. Centers for Diseases Control and Prevention. Meningococcal disease: technical and clinical information [online]. Available from URL: http://www.cdc.gov/meningitis/clinical-info.html [Accessed 2011 Aug 17]
52. Centers for Diseases Control and Prevention. Active Bacterial Core surveillance (ABCs) report: emerging infections program network. Neisseria meningitidis, 2006 [online]. Available from URL: http://www.cdc.gov/abcs/ reports-findings/survreports/mening06.pdf [Accessed 2011 Aug 17]
53. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007; 31: 3-14 (Pubitemid 46058815)
54. The European Union Invasive Bacterial Infections Surveillance Network. Invasive meningococcal disease [online]. Available from URL: http://www.ecdc.europa.eu/en/publications/Publications/1011-SUR-Annual-Epi demiological-Report-on-Communicable-Diseases-in-Europe.pdf#page= 149 [Accessed 2011 Feb 21]
55. EU-IBIS Network. Invasive Neisseria meningitidis in Europe 2006. London: Health Protection Agency, 2006 [online]. Available from URL: http://www.hpa-bioinformatics.org.uk/euibis/documents/2006-meningo.pdf [Accessed 2011 Aug 17]
56. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50: S37-44
57. Girard MP, Preziosi MP, Aguado MT, et al. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24: 4692-700 (Pubitemid 43776790)
58. Centers for Diseases Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54: 1-21
59. Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007; 26: 716-22 (Pubitemid 47424642)
60. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England. BMJ 2003; 326: 365-6 (Pubitemid 36241472)
61. Pace D, Pollard AJ. Meningococcal A, C, Y and W-135 polysaccharideprotein conjugate vaccines. Arch Dis Child 2007; 92: 909-15 (Pubitemid 47535456)
62. Centers for Diseases Control and Prevention. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep 2008: 57 462-5
63. World Health Organization. Meningitis A conjugate vaccine. Wkly Epidemiol Rec 2011; 86: 42-3
64. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/2004: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55: 887-96 (Pubitemid 43974695)
65. Jennings HJ, Lugowski C. Immunochemistry of groups A, B and C meningococcal polysaccharide- tetanus toxoid conjugates. J Immunol 1981; 127: 1011-8 (Pubitemid 11051148)
66. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50: S54-65
67. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27 Suppl. 2: B3-12
68. Nokleby H, Aavitsland P, OHallahan J, et al. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007; 25: 3080-4 (Pubitemid 46505045)
69. Kelly C, Arnold R, Galloway Y, et al. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007; 166: 817-23 (Pubitemid 47428901)
70. Galloway Y, Stehr-Green P, McNicholas A, et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B me-ningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009; 38: 413-8
71. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Surveillance Team. J Clin Microbiol 2000; 38: 323-8
72. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287: 1816-20
73. Philbin VJ, Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 2009; 65: 98-105R
74. Fleer A, Gerards LJ, Verhoef J. Host defence to bacterial infection in the neonate. J Hosp Infect 1988; 11: 320-7
75. Harvey D, Holt D, Bedford H. Bacterial meningitis in the newborn: a prospective study of mortality and morbidity. Semin Perin 1999; 23: 218-25 (Pubitemid 29295802)
76. Thaver D, Zaidi AK. Burden of neonatal infections in developing countries: a review of evidence from community-based studies. Pediatr Infect Dis J 2009; 28 Suppl. 1: S3-9
77. Puopolo KM, Madoff LC, Eichenwald EC. Early onset group B streptococcal disease in the era of maternal screening. Pediatrics 2005; 115: 1240-6 (Pubitemid 43843226)
78. Bedford H, de Louvois J, Halket S, et al. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001; 323: 533-6 (Pubitemid 32835570)
79. Klinger G, Chin CN, Beyene J, et al. Predicting the outcome of neonatal bacterial meningitis. Pediatrics 2000 Sep; 106: 477-82 (Pubitemid 30664131)
80. Zaidi AK, Thaver D, Ali SA, et al. Pathogens associated with sepsis in newborns and young infants in developing countries. Pediatr Infect Dis J 2009; 28 Suppl. 1: S10-8
81. Centers of Disease Control and Prevention. Trends in perinatal group B streptococcal disease: United States 2000-2006. Morb Mortal Wkly Rep 2009 Feb; 58: 109-12
82. Edwards MS. Group B streptococcal conjugate vaccine: a timely concept for which time has come. Hum Vaccine 2008; 4: 444-8
83. Health Protection Agency. NOIDS final MIDI report for 2009 [online]. Available from URL: http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1281952671504 [Accessed 2011 Feb 21]
84. World Health Organization. Tuberculosis [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs104/en/index.html [Accessed 2011 Feb 21]
85. Krujishaar ME, Abubakar I. Increase in extrapulmonary tuberculosis in England and Wales 1999-2006. Thorax 2009; 64: 1090-5
86. Peto HM, Pratt RH, Harrington TA, et al. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis 2009 Nov; 49: 1350-7
87. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5: 83-93 (Pubitemid 40174779)
88. Swartz MN. Bacterial meningitis: a view of the past 90 years. N Engl J Med 2004; 351: 8126-8
89. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-84 (Pubitemid 39458512)
90. Proulx N, Frechette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005; 98: 291-8
91. Miner JR, Heegaard W, Mapes A, et al. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001; 21: 387-92 (Pubitemid 33122102)
92. Visintin C, Mugglestone MA, Fields EJ, et al. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. BMJ 2010; 341: 92-8
93. Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med 2006; 34: 2758-65 (Pubitemid 44610940)
94. Kim KS. Acute bacterial meningitis in infants and children. Lancet 2010; 10: 32-42
95. Chiba N, Murayama SY, Morozumi M, et al. Rapid detection of eight causative pathogens for the diagnosis of bacterial meningitis by real-time PCR. J Infect Chemother 2009; 15: 92-8
96. Shameem S, Vinod Kumar CS, Neelagund YF. Bacterial meningitis: rapid diagnosis and microbial profile: a multicentered study. J Commun Dis 2008; 40: 111-20
97. Feldman WE. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr 1976; 88: 549-52
98. Zwahlen A, Nydegger UE, Vaudaux P, et al. Complement-mediated opsonic activity in normal and infected human cerebrospinal fluid: early response during bacterial meningitis. J Infect Dis 1982; 145: 635-46 (Pubitemid 12116449)
99. Keisari Y, Kabha K, Nissimov L, et al. Phagocyte-bacteria interactions. Adv Dent Res 1997; 11: 43-9
100. Sande MA, Sherertz RJ, Zak O, et al. Cephalosporin antibiotics in the therapy of experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis in rabbits. J Infect 1978; 137: S161-8 (Pubitemid 8344155)
101. Schaad UB, McCracken Jr GH, Loock CA, et al. Pharmacokinetics and bacteriological efficacy of moxalactam, cefotaxime cefoperazone and rocephin in experimental bacterial meningitis. J Infect Dis 1981; 143: 156-63 (Pubitemid 11147838)
102. Lutsar I, McCracken Jr GH, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27: 1117-27
103. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999; 13: 595-618 (Pubitemid 29398576)
104. Sinner SW, Tunkel AR. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North Am 2004; 18: 581-602 (Pubitemid 39078730)
105. Quagliarello VJ, Long WJ, Scheld WM. Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat: temporal sequence and role of encapsulation. J Clin Invest 1986; 77: 1084-95 (Pubitemid 16047126)
106. Quagliarello VJ, Ma A, Stukenbrok H, et al. Ultrastructural localization of albumin transport across the cerebral microvasculature during experimental meningitis in the rat. J Exp Med 1991; 174: 657-72
107. Small PM, Tauber MG, Hackbarth CJ, et al. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect Immun 1986; 52: 484-7 (Pubitemid 16117804)
108. Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007; 59: 285-91 (Pubitemid 47072068)
109. Brink M, Harberg L. Outcome of 8-hour dosing intervals with beta-lactam antibiotics in adult acute bacterial meningitis. Scand J Infect Dis 2006; 38: 772-7 (Pubitemid 44304966)
110. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967; 2: 264-5
111. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171-96
112. Bradley JS, Kaplan SL, Klugman KP, et al. Consensus: management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin. Pediatr Infect Dis J 1995; 14: 1037-41 (Pubitemid 26008453)
113. Baquero F. Pneumococcal resistance to b-lactam antibiotics: a global geographic overview. Microb Drug Resist 1995; 1 (2): 115-20
114. National Committee for Clinical Laboratory Standards, 1994. Performance standards for antimicrobial testing. Fifth informational supplement, M100-S5; 14 (16). National Committee for Clinical Laboratory Standards, Villanova (PA): The Committee, 1994
115. Marton A, Gulyas M, Muñoz R, et al. Extremely high incidence of antibiotic resistance of Streptococcus pneumoniae in Hungary. J Infect Dis 1991; 163: 524-48
116. Fenoll AI, Jado D, Vicioso A, et al. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990-1996). J Clin Microbiol 1998; 36: 3447-54
117. Hoffman J, Cetron MS, Farley MM, et al. The prevalence of drug resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481-6
118. Reacher MH, Shah A, Livermore DM, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320: 213-6 (Pubitemid 30175735)
119. Enright MC, Fenoll A, Griffiths D, et al. The three major Spanish clones of penicillin-resistant Streptococcus pneumoniae are the most common clones recovered in recent cases of meningitis in Spain. J Clin Microbiol 1999; 37: 3210-6 (Pubitemid 29455207)
120. John CC. Treatment failure with use of a third generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994; 18: 188-93 (Pubitemid 24055257)
121. Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-80
122. Tan TQ, Mason EO, BarsonWJ, et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillinnonsusceptible Streptococcus pneumoniae. Pediatrics 1998; 102: 1369-75 (Pubitemid 28550828)
123. Friedland IR, Shelton S, Paris M, et al. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1993; 12: 196-200 (Pubitemid 23101946)
124. Tan TQ, Schutze GE, Mason EO, et al. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1994; 38: 918-23 (Pubitemid 24150815)
125. Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin- resistant streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1988-92
126. Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37: 1630-6 (Pubitemid 23226374)
127. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000; 181: 369-73 (Pubitemid 30049073)
128. Viladrich PF, Guidol F, Liñares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35: 2467-72
129. Paris MM, Hickey SM, UscherMI, et al. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994; 38: 1320-4 (Pubitemid 24170714)
130. Thomas R, Le Tulzo Y, Bouget J, et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. Intensive Care Med 1999; 25: 475-80 (Pubitemid 29240443)
131. Henderson KL, Muller-Pebody B, Ladhani S. Vancomycin may not be necessary. BMJ 2010; 341: c4704
132. Paris MM, Ramilo O, McCracken Jr GH. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995; 39: 2171-5
133. Ruckinger S, von Kries R, Siedler A, et al. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 2009; 28: 118-22
134. Brandileone MC, Casagrande ST, Guerra ML, et al. Increase in numbers of beta-lactam-resistant invasive Streptococcus pneumoniae in Brazil and the impact of conjugate vaccine coverage. J Med Microbiol 2006; 55: 567-74
135. Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48: 2101-7 (Pubitemid 38691605)
136. Van Esso D, Fontanals D, Uriz S, et al. Neisseria meningitidis strains with decreased susceptibility to penicillin. Pediatr Infect Dis J 1987; 6: 438-9 (Pubitemid 17072083)
137. Saez Nieto JA, Vazquez JA. Moderate resistance to penicillin in Neisseria meningitidis. Microbiologia 1997; 13: 337-42
138. Jones DM, Sutcliffe EM. Meningococci with reduced susceptibility to penicillin. Lancet 1990; 335: 863-4 (Pubitemid 20113777)
139. Luaces Cubells C, Garcia Garcia JJ, Roca Martinez J, et al. Clinical data in children with meningococcal meningitis in a Spanish hospital. Acta Paediatr 1997; 86: 26-9 (Pubitemid 27047149)
140. Latorre C, Gene A, Juncosa T, et al. Neisseria meningitidis: evolution of penicillin resistance and phenotype in a childrens hospital in Barcelona, Spain. Acta Pediatr 2000; 89: 661-5 (Pubitemid 30624908)
141. World Health Organization. Standardized treatment of bacterialmeningitis in Africa in epidemic and non-epidemic situations [online]. Available from URL: http://www.who.int/csr/resources/publications/meningitis/WHO-CDS-EPR-2007-3.pdf [Accessed 2011 Feb 23]
142. Deghmane A, Alonso J, Taha M. Emerging drugs for acute bacterial meningitis. Expert Opin Emerging Drugs 2009; 14: 381-93
143. Health Protection Agency. Guidance for public health management of meningococcal disease in the UK [online]. Available from URL: http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1194947389261 [Accessed 2011 Apr 11]
144. Nolte O. Rifampicin resistance in Neisseria meningitidis: evidence from a study of sibling strains: description of new mutations and notes on population genetics. J Antimicrob Chemother 1997; 39: 747-55 (Pubitemid 27296415)
145. Carter PE, Abadi FJ, Yakubu DE, et al. Molecular characterization of rifampin-resistant Neisseria meningitidis. Antimicrob Agents Chemother 1994; 38: 1256-61 (Pubitemid 24170704)
146. Stefanelli P, Fazio C, La Rosa G, et al. Rifampicin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains. J Antimicrob Chemother 2001; 47: 219-22 (Pubitemid 32149533)
147. Tzanakaki G, Blackwell CC, Kremastinou J, et al. Antibiotic sensitivities of Neisseria meningitidis isolates from patients and carriers in Greece. Epidemiol Infect 1992; 108: 449-55
148. Raghunathan L, Ramsay M, Borrow R, et al. Clinical features, laboratory findings and management of meningococcal meningitis in England and Wales: report of a 1997 survey. Meningococcal meningitis: 1997 survey report. J Infect 2000; 40: 74-9 (Pubitemid 30157778)
149. Alcala B, Saledo C, de la Fuente L, et al. Neisseria meningitidis showing decreased susceptibility to ciprofloxacin: first report in Spain. J Antimicrob Chemother 2004; 53: 409 (Pubitemid 38239990)
150. Gruneberg RN, Felmingham D. Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of communityacquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996; 25: 169-81 (Pubitemid 26392168)
151. Johnson AW, Mokuolu OA, Onile BA. Chloramphenicol-resistant Haemophilus influenzae meningitis in young urban Nigerian children. Acta Pediatr 1992; 81: 941-3
152. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46 (Pubitemid 36986885)
153. Kim BN, Woo JH, Kim YS, et al. Time-kill studies of antimicrobial combinations including ceftriaxone, vancomycin and meropenem against cephalosporin streptococcus pneumoniae. Chemotherapy 2000; 46: 303-8
154. Ladhani S, Neely F, Heath PT, et al. Recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease. J Infect 2010; 58: 3-14
155. Baldwin CM, Lyseng-Williamson KA, Keam J. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008; 68: 803-38 (Pubitemid 351559562)
156. Odio CM, Puig JR, Feris JM, et al. Prospective, randomized, investigatorblinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 1999; 18: 581-90 (Pubitemid 29350323)
157. Buckingham SC, Davis Y, English BK. Pneumococcal susceptibility to meropenem in a mid-south childrens hospital. South Med J 2002; 95: 1293-6 (Pubitemid 36109339)
158. Kosowska-Shich K, McGhee P, Appelbaum PC. Binding of faropenem and other (beta)-lactam susceptibilities. Antimicrob Agents Chemother 2009; 53: 2176-80
159. Lodise Jr TP, Nau R, Kinzig M, et al. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. DiagnMicrobiol Infect Dis 2007; 58: 445-52 (Pubitemid 47202025)
160. Lutsar I, Friedland IR, Wubbel L, et al. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1998; 42: 2650-5 (Pubitemid 28462909)
161. Rodriguez-Cerrato V, Ghaffar F, Saavedra J, et al. BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2001; 45: 3098-103 (Pubitemid 32988834)
162. Rodriguez-Cerrato V, McCoig CC, Saacedra J, et al. Garenoxacin (BMS- 284756) and moxifloxacin in experimental meningitis caused by vancomycintolerant pneumococcus. Antimicrob Agents Chemother 2003; 47: 211-5 (Pubitemid 36070366)
163. Suntur BM, Yurtseven T, Sipahi OR, et al. Rifampicin + ceftriaxone versus vanocmycin + ceftriaxone in the treatment of penicillin- and cephalosporinresistant pneumococcal meningitis in an experimental rabbit model. Int J Antimicrob Agents 2005; 26: 258-60 (Pubitemid 41219614)
164. Faella F, Pagliano P, Fusco U, et al. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillinresistant strains. Clin Microbiol Infect 2006; 12: 391-4 (Pubitemid 43337531)
165. Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48: 3928-33 (Pubitemid 39304623)
166. Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology and progress. N Engl J Med 1992; 327: 864-72
167. Waage A, Halstensen A, Shalaby R, et al. Local production of tumor necrosis factor alpha, interleukin 1 and interleukin 6 in meningococcal meningitis: relation to the inflammatory response. J Exp Med 1989; 170: 1859-67 (Pubitemid 20010069)
168. van Furth AM, Seijmonsbergen EM, Langermans JAM, et al. High Levels of interleukin 10 and tumor necrosis factor alpha in cerebrospinal fluid during the onset of bacterial meningitis. Clin Infect Dis 1995; 21: 220-2
169. Ramilo O, Saez-Llorens X, Mertsola J, et al. Tumor necrosis factor a/cachectin and interleukin 1b initiate meningeal inflammation. J Exp Med 1990; 172: 497-507 (Pubitemid 20248391)
170. Saex-Llorens X, Ramilo O, Mustafa MM, et al. Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications. J Pediatr 1990; 116: 671-84 (Pubitemid 20162813)
171. Weiss J, Elsbach P, Shu C, et al. Human bactericidal/permeability- increasing protein and a recombinant NH2-terminal fragment cause killing of serumresistant Gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 1992; 90: 1122-30
172. von Asmuth EJU, Dentener MA, Bazil V, et al. Anti-CD14 antibodies reduce responses of cultured endothelial cells to endotoxin. Immunology 1993; 80: 78-83 (Pubitemid 23284192)
173. Tuomanem EL, Saukkonen K, Sande S, et al. Reduction of inflammation, tissue damage and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leucocytes. Exp Med 1989; 170: 959-69 (Pubitemid 19226676)
174. Levin M, Quint P, Goldstein B, et al. Recombinant bactericidal/ permeabilityincreasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet 2000; 356: 961-7
175. Lebel MH, Freij RJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis: results of two double blind, placebo controlled trials. N Engl J Med 1988; 319: 964-71
176. Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991; 324: 1525-31
177. Girgis NI, Farid Z, Mikhail IA, et al. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis J 1989; 8: 848-51 (Pubitemid 20018839)
178. Kanra GY, OzenKD, SecmeerG, et al. Beneficial effects of dexamethasone in children with pneumococcal meningitis. Pediatr Infect Dis J 1995; 14: 490-4
179. Thomas R, Le Tulzo Y, Bonget C, et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. Intensive Care Med 1999 May; 25: 475-80 (Pubitemid 29240443)
180. van de Beek D, de Gans J, McIntyre P, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007; (1): CD004405
181. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: ameta-analysis of individual patient data. Lancet 2010; 9: 254-63
182. Ricard J, Wolff M, Lacherade J, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 2007; 44: 250-5 (Pubitemid 46079990)
183. American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, editor. Red book: 2009 report of the Committee on Infectious Diseases, 28th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2009: 524-35
184. Chaudhari A, Martinez-Martin P, Kennedy PG, et al. EFNS guideline on the management of community-acquired bacterial meningitis in older children and adults. EFNS Task Force. Eur J Neurol 2008; 15: 649-59
185. Peltola H, Roine I, Fernandez J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007; 45: 1277-86 (Pubitemid 351411900)
186. Peltola H, Roine I. Improving the outcomes in children with bacterial meningitis. Opin Infect Dis 2009; 22: 250-5
187. Karageorgopoulos DE, Valkimadi PE, Kapaskelis A, et al. Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. Arch Dis Child 2009; 94: 607-14
188. Radetsky M. Duration of treatment in bacterial meningitis: a historical inquiry. Pediatr Infect Dis J 1990; 9: 2-9 (Pubitemid 20157094)
189. Martin E, Hohl P, Guggi T, et al. Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: results of a Swiss multicenter study: part 1. Clinical results. Infection 1990; 18: 70-7 (Pubitemid 20123446)